Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest Expenses (2016 - 2025)

Collegium Pharmaceutical has reported Interest Expenses over the past 9 years, most recently at $19.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $19.3 million for Q4 2025, down 14.84% from a year ago — trailing twelve months through Dec 2025 was $82.3 million (up 11.27% YoY), and the annual figure for FY2025 was $82.3 million, up 11.27%.
  • Interest Expenses for Q4 2025 was $19.3 million at Collegium Pharmaceutical, down from $21.8 million in the prior quarter.
  • Over the last five years, Interest Expenses for COLL hit a ceiling of $22.7 million in Q4 2024 and a floor of $4.8 million in Q4 2021.
  • Median Interest Expenses over the past 5 years was $19.2 million (2022), compared with a mean of $16.2 million.
  • Biggest five-year swings in Interest Expenses: crashed 38.52% in 2021 and later soared 332.52% in 2022.
  • Collegium Pharmaceutical's Interest Expenses stood at $4.8 million in 2021, then surged by 332.52% to $20.6 million in 2022, then decreased by 6.29% to $19.3 million in 2023, then rose by 17.49% to $22.7 million in 2024, then fell by 14.84% to $19.3 million in 2025.
  • The last three reported values for Interest Expenses were $19.3 million (Q4 2025), $21.8 million (Q3 2025), and $20.5 million (Q2 2025) per Business Quant data.